Overview
MOA
Impact
X
Procedure
Guidelines
Resources
Clinical Library
Reimbursement
Grants
Order Cysview
Overview
White vs. Blue Light
Patient Stories
Bladder Cancer Overview
X
Resources
Home
BLC™ with Cysview®
>
News
Health Care Professionals
>
Find a BLC with Cysview Center
X
Cysview LogoHamburger Menu Icon
Menu
Find a BLC with Cysview Center
Health Care Professionals

OVERVIEW

See More. Resect More.

With more than 696,440 people living with bladder cancer in the U.S.,15 there is a high unmet medical need for the improved diagnosis and management of non-muscle invasive bladder cancer (NMIBC). The disease is not only an emotional and physical burden on patients and caregivers, but also a financial strain on health care resources, with the highest lifetime treatment costs per patient of all cancers.11

To alleviate this weight and reduce frequent, lifelong follow-up visits, health care professionals must perform thorough exams and resections from patients’ very first procedures. Blue Light Cystoscopy (BLC™) with Cysview® helps make this possible.

Confidence at First Sight

BLC with Cysview significantly improves the detection of NMIBC, compared to white light cystoscopy alone.4 The imaging agent Cysview (hexaminolevulinate HCl) glows bright pink under blue light, highlighting even hard-to-see tumors, including residual. The more clearly bladder cancer lesions can be identified, the more thoroughly they can be removed by transurethral resection of bladder tumor (TURBT).

Diagram showing the imaging agent insertion
Reproduced from Bladder Cancer: A Patient-Friendly Guide to Understanding Your Diagnosis and Treatment Options. Copyright © 2017 David Pulver

24.9%
of patients with ≥1 additional Ta/T1 tumor detected with BLC with Cysview leading to better tumor resection.9

20.7%
of patients with primary BC with ≥1 additional Ta/T1 tumor detected with Cysview.9

27.7%
of patients with recurrent BC with ≥1 additional Ta/T1 tumor detected with Cysview.9

Better detection. Better diagnosis. Better management. Start optimizing patient care at your facility — order Cysview today.

Bladder cancer icon

BLC with
Cysview Impact

Discover the benefits of a complete TURBT.
Learn More
Procedure icon

The
Procedure

Be prepared before you perform BLC with Cysview.
Learn More
Order Cysview icon

Order
Cysview

Start improving patient care at your facility.
Learn More

Are you a patient or caregiver wanting more information on blue light cystoscopy with Cysview?

Return to BLC with Cysview

Prescribing Information

Cysview is an optical imaging agent indicated for use in the cystoscopic detection of carcinoma of the bladder, including carcinoma in situ (CIS), among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy, or in patients undergoing surveillance cystoscopy for carcinoma of the bladder. Cysview is used with the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) system to perform Blue Light Cystoscopy (BLCTM) as an adjunct to the white light cystoscopy.

Important Safety Information About Cysview® (hexaminolevulinate HCl)

Cysview is not a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer. 

Anaphylactoid shock, hypersensitivity reactions, bladder pain, cystitis, and abnormal urinalysis have been reported after administration of Cysview. The most common adverse reactions seen in clinical trials were bladder spasm, dysuria, hematuria, and bladder pain. 

Cysview should not be used in patients with porphyria, gross hematuria, or with known hypersensitivity to hexaminolevulinate or any derivative of aminolevulinic acid. Cysview may fail to detect some malignant lesions. False-positive fluorescence may occur due to inflammation, cystoscopic trauma, scar tissue, previous bladder biopsy and recent BCG therapy or intravesical chemotherapy. No specific drug interaction studies have been performed. 

Safety and effectiveness have not been established in pediatric patients. There are no available data on Cysview use in pregnant women. Adequate reproductive and developmental toxicity studies in animals have not been performed. Systemic absorption following administration of Cysview is expected to be minimal. There are no data on the presence of hexaminolevulinate in human or animal milk, the effects on a breastfed infant, or the effects on milk production. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for Cysview and any potential adverse effects on the breastfed infant from Cysview or from the underlying maternal condition. 

Cysview is approved for use with the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) system. For system set up and general information for the safe use of the PDD system, please refer to the KARL STORZ instruction manuals for each of the components. 

Prior to Cysview administration, read the Full Prescribing Information and follow the preparation and reconstitution instructions.

Photocure Logo

Prescribing Information

Cysview is an optical imaging agent indicated for use in the cystoscopic detection of carcinoma of the bladder, including carcinoma in situ (CIS), among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy, or in patients undergoing surveillance cystoscopy for carcinoma of the bladder. Cysview is used with the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) system to perform Blue Light Cystoscopy (BLCTM) as an adjunct to the white light cystoscopy.

Important Safety Information About Cysview® (hexaminolevulinate HCl)

Cysview is not a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer. 

Anaphylactoid shock, hypersensitivity reactions, bladder pain, cystitis, and abnormal urinalysis have been reported after administration of Cysview. The most common adverse reactions seen in clinical trials were bladder spasm, dysuria, hematuria, and bladder pain. 

Cysview should not be used in patients with porphyria, gross hematuria, or with known hypersensitivity to hexaminolevulinate or any derivative of aminolevulinic acid. Cysview may fail to detect some malignant lesions. False-positive fluorescence may occur due to inflammation, cystoscopic trauma, scar tissue, previous bladder biopsy and recent BCG therapy or intravesical chemotherapy. No specific drug interaction studies have been performed. 

Safety and effectiveness have not been established in pediatric patients. There are no available data on Cysview use in pregnant women. Adequate reproductive and developmental toxicity studies in animals have not been performed. Systemic absorption following administration of Cysview is expected to be minimal. There are no data on the presence of hexaminolevulinate in human or animal milk, the effects on a breastfed infant, or the effects on milk production. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for Cysview and any potential adverse effects on the breastfed infant from Cysview or from the underlying maternal condition. 

Cysview is approved for use with the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) system. For system set up and general information for the safe use of the PDD system, please refer to the KARL STORZ instruction manuals for each of the components. 

Prior to Cysview administration, read the Full Prescribing Information and follow the preparation and reconstitution instructions.

Photocure Logo
<  PREV  News
BACK TO TOP
NEXT  MOA  >

MOA